Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis

Vivek Jain, Maya L Petersen, Teri Liegler, Dathan M Byonanebye, Dalsone Kwarisiima, Gabriel Chamie, Norton Sang, Doug Black, Tamara D Clark, Andras Ladai, Albert Plenty, Jane Kabami, Emmanuel Ssemmondo, Elizabeth A Bukusi, Craig R Cohen, Edwin D Charlebois, Moses R Kamya, Diane V Havlir, SEARCH Collaboration, Vivek Jain, Maya L Petersen, Teri Liegler, Dathan M Byonanebye, Dalsone Kwarisiima, Gabriel Chamie, Norton Sang, Doug Black, Tamara D Clark, Andras Ladai, Albert Plenty, Jane Kabami, Emmanuel Ssemmondo, Elizabeth A Bukusi, Craig R Cohen, Edwin D Charlebois, Moses R Kamya, Diane V Havlir, SEARCH Collaboration

Abstract

Background: As sub-Saharan Africa transitions to a new era of universal antiretroviral therapy (ART), up-to-date assessments of population-level HIV RNA suppression are needed to inform interventions to optimise ART delivery. We sought to measure population viral load metrics to assess viral suppression and characterise demographic groups and geographical locations with high-level detectable viraemia in east Africa.

Methods: The Sustainable East Africa Research in Community Health (SEARCH) study is a cluster-randomised controlled trial of an HIV test-and-treat strategy in 32 rural communities in Uganda and Kenya, selected on the basis of rural setting, having an approximate population of 10 000 people, and being within the catchment area of a President's Emergency Plan for AIDS Relief-supported HIV clinic. During the baseline population assessment in the SEARCH study, we did baseline HIV testing and HIV RNA measurement. We analysed stable adult (aged ≥15 years) community residents. We defined viral suppression as a viral load of less than 500 copies per mL. To assess geographical sources of transmission risk, we established the proportion of all adults (both HIV positive and HIV negative) with a detectable viral load (local prevalence of viraemia). We defined transmission risk hotspots as geopolitical subunits within communities with an at least 5% local prevalence of viraemia. We also assessed serodiscordant couples, measuring the proportion of HIV-positive partners with detectable viraemia. The SEARCH study is registered with ClinicalTrials.gov, number NCT01864603.

Findings: Between April 2, 2013, and June 8, 2014, of 303 461 stable residents, we enumerated 274 040 (90·3%), of whom 132 030 (48·2%) were adults. Of these, 117 711 (89·2%) had their HIV status established, of whom 11 964 (10·2%) were HIV positive. Of these, we measured viral load in 8828 (73·8%) people. Viral suppression occurred in 3427 (81·6%) of 4202 HIV-positive adults on ART and 4490 (50·9%) of 8828 HIV-positive adults. Regional viral suppression among HIV-positive adults occurred in 881 (48·2%) of 1827 people in west Uganda, 516 (45·0%) of 1147 in east Uganda, and 3093 (52·8%) of 5854 in Kenya. Transmission risk hotspots occurred in three of 21 parishes in west Uganda and none in east Uganda and in 24 of 26 Kenya geopolitical subunits. In Uganda, 492 (2·9%) of 16 874 couples were serodiscordant: in 287 (58·3%) of these couples, the HIV-positive partner was viraemic (and in 69 [14·0%], viral load was >100 000 copies per mL). In Kenya, 859 (10·0%) of 8616 couples were serodiscordant: in 445 (53·0%) of these couples, the HIV-positive partner was viraemic (and in 129 [15%], viral load was >100 000 copies per mL).

Interpretation: Before the start of the SEARCH trial, 51% of east African HIV-positive adults had viral suppression, reflecting ART scale-up efforts to date. Geographical hotspots of potential HIV transmission risk and detectable viraemia among serodiscordant couples warrant intensified interventions.

Funding: National Institute of Allergy and Infectious Diseases (National Institutes of Health) and the President's Emergency Plan for AIDS Relief.

Copyright © 2017 Elsevier Ltd. All rights reserved.

Figures

Figure 1. CONSORT Diagram
Figure 1. CONSORT Diagram
Selection of 8,828 adults for analysis who had stable residence in study communities, underwent HIV testing, and had HIV RNA level (viral load) determined. Three of 32 communities in the SEARCH Study were excluded because viral load testing utilized a higher lower limit of quantitation (

Figure 2. Local community prevalence of viremia…

Figure 2. Local community prevalence of viremia by region

(A) Geographic maps showing locations of…

Figure 2. Local community prevalence of viremia by region
(A) Geographic maps showing locations of West Uganda study communities [map + inset map]. For each community, the local prevalence of viremia is indicated (% of adults [regardless of HIV status] who had HIV viremia). (B) Maps showing East Uganda community locations and local prevalence of viremia. (C) Maps showing Kenya community locations and local prevalence of viremia.

Figure 3. Viral suppression by sero-discordancy characteristics…

Figure 3. Viral suppression by sero-discordancy characteristics of male-female couples

(A) Overall numbers of male-female…

Figure 3. Viral suppression by sero-discordancy characteristics of male-female couples
(A) Overall numbers of male-female couples [n=25,490] defined by the male and female partner being either HIV-negative, HIV-positive with VL>500 c/mL, or HIV-positive with VL>500 c/mL. Sero-discordant couples with lower risk (light blue boxes) and higher risk (red boxes) are indicated. Analogous tables of sero-discordant couples in (B) West Uganda [n=7,682 couples], (C) East Uganda [n=9,192 couples], and (D) Kenya [8,616 couples] are shown.
Figure 2. Local community prevalence of viremia…
Figure 2. Local community prevalence of viremia by region
(A) Geographic maps showing locations of West Uganda study communities [map + inset map]. For each community, the local prevalence of viremia is indicated (% of adults [regardless of HIV status] who had HIV viremia). (B) Maps showing East Uganda community locations and local prevalence of viremia. (C) Maps showing Kenya community locations and local prevalence of viremia.
Figure 3. Viral suppression by sero-discordancy characteristics…
Figure 3. Viral suppression by sero-discordancy characteristics of male-female couples
(A) Overall numbers of male-female couples [n=25,490] defined by the male and female partner being either HIV-negative, HIV-positive with VL>500 c/mL, or HIV-positive with VL>500 c/mL. Sero-discordant couples with lower risk (light blue boxes) and higher risk (red boxes) are indicated. Analogous tables of sero-discordant couples in (B) West Uganda [n=7,682 couples], (C) East Uganda [n=9,192 couples], and (D) Kenya [8,616 couples] are shown.

References

    1. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807.
    1. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808–822.
    1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015:1–78.
    1. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLOS ONE. 2010;5(6):e11068.
    1. Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–353.
    1. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, et al. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013;56(4):598–605.
    1. Miller WC, Powers KA, Smith MK, Cohen MS. Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis. 2013;13(5):459–464.
    1. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2014. pp. 1–40.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
    1. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–971.
    1. Tanser F, Barnighausen T, Cooke GS, Newell ML. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol. 2009;38(4):1008–1016.
    1. Vella S, Schwartlander B, Sow SP, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26(10):1231–1241.
    1. Joint United Nations Programme on HIV/AIDS. How AIDS changed everything: MDG 6 executive summary. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2015. pp. 1–140.
    1. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016;3(4)
    1. Maman D, Zeh C, Mukui I, Kirubi B, Masson S, Opolo V, et al. Cascade of HIV care and population viral suppression in a high-burden region of Kenya. AIDS. 2015;29(12):1557–1565.
    1. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al. HIV care continuum in Rwanda: a cross-sectional analysis of the national programme. Lancet HIV. 2015;2(5):e208–e215.
    1. Justman J, Ellman T, Donnell D, Duong Y, Reed J, Bicego G, et al. Population HIV Viral Load Estimate in Swaziland: Assessing ART Program Effectiveness and Transmission Potential. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; March 5, 2013; Atlanta, GA. Abstract 96. 2013.
    1. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis. 2016;62(8):1043–1048.
    1. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2):171–181.
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929.
    1. Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016;3(3):e111–e119.
    1. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural Uganda. PLOS ONE. 2012;7(8):e43400.
    1. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403–1409.
    1. Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. Alcohol Res Health. 2010;33(3):280–287.
    1. Fatch R, Emenyonu NI, Muyindike W, Kekibiina A, Woolf-King S, Hahn JA. Alcohol Interactive Toxicity Beliefs and ART Non-adherence Among HIV-Infected Current Drinkers in Mbarara, Uganda. AIDS Behav. 2016
    1. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, Muyindike WR, et al. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 2013;10(1):e1001369–e1001369.
    1. Brouwer KC, Rusch ML, Weeks JR, Lozada R, Vera A, Magis-Rodriguez C, et al. Spatial Epidemiology of HIV among Injection Drug Users in Tijuana, Mexico. Ann Assoc Am Geogr. 2012;102(5):1190–1199.
    1. Hoshi T, Fuji Y, Nzou SM, Tanigawa C, Kiche I, Mwau M, et al. Spatial Distributions of HIV Infection in an Endemic Area of Western Kenya: Guiding Information for Localized HIV Control and Prevention. PLOS ONE. 2016;11(2):e0148636.
    1. Izumi K, Ohkado A, Uchimura K, Murase Y, Tatsumi Y, Kayebeta A, et al. Detection of Tuberculosis Infection Hotspots Using Activity Spaces Based Spatial Approach in an Urban Tokyo, from 2003 to 2011. PLOS ONE. 2015;10(9):e0138831.
    1. Morris CN, Ferguson AG. Estimation of the sexual transmission of HIV in Kenya and Uganda on the trans-Africa highway: the continuing role for prevention in high risk groups. Sex Transm Infect. 2006;82(5):368–371.
    1. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–2160.
    1. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples. J Infect Dis. 2012;205(3):358–365.
    1. Chamie G, Kabami J, Ssemmondo E, Clark TD, Bukusi E, Petersen M, et al. 94% Population HIV Testing Coverage With Repeat Hybrid Mobile Testing in East Africa. Program and Abstracts of the 2016 Conference on Retroviruses and Opportunistic Infections; February 22–25, 2016; Boston, MA. 2016. Abstract 979. 2016.

Source: PubMed

3
Subskrybuj